For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Formulary Search > PAD Profile : Atogepant - Migraine (prevention)
PAD Profile : Atogepant - Migraine (prevention)
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Botulinum toxin type A
- Flunarizine dihydrochloride
- Pizotifen malate
- Erenumab
- Galcanezumab
- Fremanezumab
- Propranolol hydrochloride
- Topiramate
- Amitriptyline hydrochloride
- Gabapentin
- Pregabalin
- Rimegepant
- Candesartan cilexetil
- Clonidine hydrochloride
Other Indications
- Lambert-Eaton myasthenic syndrome (LEMS)
- Pain
- Osteoarthritis
- Erectile dysfunction
- Hyperuricaemia and Gout
- Dysphagia
- Low sexual desire in menopausal women
- Psoriasis
- Atopic dermatitis
- Multiple sclerosis
- Duchenne muscular dystrophy
- Multiple sclerosis
- Systemic Lupus Erythematosus
- Inclusion body myositis
- Systemic Lupus Erythematosus
- Duchenne muscular dystrophy
- Systemic Lupus Erythematosus
- Multiple sclerosis
- Short bowel syndrome
- Any paediatric use
- Erectile dysfunction combination therapy
- Children and young people with Epilepsy
- Diabetes Mellitus
- Interface Prescribing Policy (IPP)
- Restless Leg Syndrome
- Pain (Chronic)
- Narcolepsy
- All
- Atopic dermatitis
- Psoriasis
- Inflammatory bowel disease
- Ulcerative colitis - moderately to severely active
- Migraine (prevention)
- Dry eyes
- Cancer
- Diarrhoea
- Ulcerative colitis - moderately to severely active
- Non-radiographic axial spondyloarthritis
- Photoaggravated dermatoses
- Photodermatoses
- Metabolic disorders
- Insomnia in adults
- Cardiomyopathy
- Epidermolysis bullosa
- Photoaggravated dermatoses
- Psoriasis
- Psoriatic arthritis
- Photodermatoses
- Photodermatoses
- Photoaggravated dermatoses
- Catheter maintenance solutions
- Dry eyes
- Dry eyes
- Dry eyes
- Dry eyes
- Dry eyes
- Dysphagia
- Prurigo nodularis
- Vitamin D deficiency and insufficiency
- Osteoporosis
- Pain
- Pustular psoriasis
- Mucus clearance
- Atopic dermatitis
- Alopecia
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Smoking cessation
- Pain
- Homozygous familial hypercholesterolaemia
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Metabolic disorders
- Concious sedation
- Premedication
- post Bariatric surgery
- Erectile dysfunction
- Parkinson's disease
- Myasthenia gravis
Additional Documents
No additional documents returned.
Committee Recommendations
This drug has not yet been assessed for formulary status.
It has not yet been evaluated by NICE or the Surrey Heartlands ICS Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug.
NICE are due to publish guidance on this drug in Apr 2024 and this will be considered by the APC within 90 days of publication